Grail Inc at Goldman Sachs Healthcare Conference Transcript
Hi, everyone. I'm Evie Kozlowski, the Life Science Tools and Diagnostics Analyst here at Goldman Sachs. I'm joined here by Aaron Freidin, the CFO of GRAIL. Thank you so much for joining us.
Yeah, thanks for having us.
Maybe to kick us off, start by helping investors get oriented with the story, a quick overview of how you're building out the multi-cancer early detection market and sort of what you're most focused on right now.
Yeah, definitely. We're really excited about what we've built over the last 10 years. Multi-cancer early detection was just an idea. Now we've got a product on the market. We've got lots of interventional data. We've got RCT data that we released at ASCO, really showing that this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
